Hepion Pharmaceuticals Inc HEPA:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 04/24/24 EDT
1.32UNCH (UNCH)
Volume
36,380
52 week range
1.22 - 20.66
Loading...
  • Open1.52
  • Day High1.54
  • Day Low1.30
  • Prev Close1.49
  • 52 Week High20.66
  • 52 Week High Date05/23/23
  • 52 Week Low1.22
  • 52 Week Low Date04/22/24

Key Stats

  • Market Cap7.224M
  • Shares Out5.47M
  • 10 Day Average Volume0.07M
  • Dividend-
  • Dividend Yield-
  • Beta1.70
  • YTD % Change-59.26

KEY STATS

  • Open1.52
  • Day High1.54
  • Day Low1.30
  • Prev Close1.49
  • 52 Week High20.66
  • 52 Week High Date05/23/23
  • 52 Week Low1.22
  • 52 Week Low Date04/22/24
  • Market Cap7.224M
  • Shares Out5.47M
  • 10 Day Average Volume0.07M
  • Dividend-
  • Dividend Yield-
  • Beta1.70
  • YTD % Change-59.26

RATIOS/PROFITABILITY

  • EPS (TTM)-12.41
  • P/E (TTM)-0.11
  • Fwd P/E (NTM)-0.11
  • EBITDA (TTM)-45.191M
  • ROE (TTM)-182.07%
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date05/13/2024
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Hepion Pharmaceuticals Inc

 

Profile

MORE
Hepion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development of drug therapy for treatment of chronic liver diseases. This therapeutic approach targets fibrosis, inflammation, and the treatment hepatocellular carcinoma (HCC) associated with non-alcoholic steatohepatitis (NASH), viral hepatitis and other liver diseases. The Company's cyclophilin inhibitor, rencofilstat is developed to offer benefits to address multiple complex...
John Brancaccio CPA
Independent Chairman of the Board
John Cavan
Interim Chief Executive Officer
Address
399 Thornall St
Edison, NJ
08837-2236
United States